BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15238418)

  • 1. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.
    Barrans SL; Fenton JA; Banham A; Owen RG; Jack AS
    Blood; 2004 Nov; 104(9):2933-5. PubMed ID: 15238418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic markers and gene abnormalities in subgroups of diffuse large B-cell lymphoma: single center experience.
    Korać P; Dominis M
    Croat Med J; 2008 Oct; 49(5):618-24. PubMed ID: 18925695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.
    He M; Gao L; Zhang S; Tao L; Wang J; Yang J; Zhu M
    Gastric Cancer; 2014; 17(3):431-41. PubMed ID: 24232982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
    Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
    Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The significance of FOXP1 in diffuse large B-cell lymphoma.
    Gascoyne DM; Banham AH
    Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases.
    Tzankov A; Pehrs AC; Zimpfer A; Ascani S; Lugli A; Pileri S; Dirnhofer S
    J Clin Pathol; 2003 Oct; 56(10):747-52. PubMed ID: 14514777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma.
    Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X
    Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
    Flori M; Schmid CA; Sumrall ET; Tzankov A; Law CW; Robinson MD; Müller A
    Blood; 2016 Mar; 127(11):1438-48. PubMed ID: 26729899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
    Brown PJ; Ashe SL; Leich E; Burek C; Barrans S; Fenton JA; Jack AS; Pulford K; Rosenwald A; Banham AH
    Blood; 2008 Mar; 111(5):2816-24. PubMed ID: 18077790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China.
    Hu CR; Wang JH; Wang R; Sun Q; Chen LB
    Acta Histochem; 2013 Mar; 115(2):137-43. PubMed ID: 22809882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
    Barrans SL; Evans PA; O'Connor SJ; Kendall SJ; Owen RG; Haynes AP; Morgan GJ; Jack AS
    Clin Cancer Res; 2003 Jun; 9(6):2133-9. PubMed ID: 12796378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.
    Barrans SL; Fenton JA; Ventura R; Smith A; Banham AH; Jack AS
    Haematologica; 2007 Jun; 92(6):863-4. PubMed ID: 17550867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
    Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
    Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
    Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.